Mark Dampier: Biotechnology could boost income fund – Spend & Save – Money – The Independent Saturday 22 February 2014
My Account
Logout
Register
Login
Register for INDEPENDENT VOICES now to comment on the Independent site, sign up for newsletters, react to articles and more… Already a member? click here to sign in Forgot password?
Don’t have an account yet? Join Now! We’ve found an existing account with the given email. To link the social network identity with your site account, please provide the site password for the provided email. Email: Password: Forgot your password ? Email: Registration indicates fields that are mandatory *
Email * Password * Confirm Password * First name * Surname * Postcode * Country * United Kingdom United States Republic of Ireland Rest of the World Mobile phone number Username * Gender * Male Female Year of birth * — 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 The Independent has a range of email newsletters simply choose which ones you want to receive.
Please select the newsletters you would like to receive from The Independent
IndyNews email: Early morning news headlines (Monday-Friday) Independent Voices newsletter: Updates with the best of our Opinion content IndyFootball email: Lunchtime football and sport headlines (Monday-Friday) Independent Travel newsletter: All the latest travel news and great offers (every Friday) Indy Arts and Entertainment newsletter: All the latest from the world of arts and entertainment (every Monday) The Independent Competitions and Offers email: The best new prizes, offers and bargains (every Friday) Comment Reply Notification Occasionally we would like to send you emails detailing specific offers, from us or carefully selected partners. If you would like to receive these then please tick the appropriate boxes below. We will never pass on your details to anyone else.
I would like to receive additional offers and information from The Independent I would like to receive additional offers and information sent by The Independent on behalf of carefully selected partners Terms and Conditions
* I have read, understood and agree to be bound by the terms and conditions of Independent Digital News and Media Limited Registration * indicates fields that are mandatory
Email * Password * Confirm Password * First name * Surname * Username * Terms and Conditions
* I have read, understood and agree to be bound by the terms and conditions of Independent Mail Sent for Registration Confirmation. A confirmation email has been sent. Please activate your account by clicking on the activation link sent in your mail box. Flag Sent for Moderation. The comment you selected has been flagged to the moderators. Thank you for bringing it to our attention.
Elephant Campaign
eBooks
i Jobs
Dating
Shop
News
Images
Voices
Sport
Tech
Life
Property
Arts + Ents
Travel
Money Spend & Save
Loans & Credit Compare Cards
Mortgages Advice
Pensions
Insurance
Tax
Money Transfers
Broadband
Health Insurance
Your Money
IFA’s
IndyBest
Blogs
Student
Offers
Ukraine Late train compensation Cheerleading George Osborne Greece Michael Gove Money >Spend & Save Mark Dampier: Biotechnology could boost income fund
Mark Dampier Friday 21 February 2014
Print Your friend’s email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email When Bill Mott launched the PSigma Income fund in 2007 I suggested it was a good choice for income and growth investors. Unfortunately performance has not lived up to expectations. It hasn’t helped that the fund was launched at the peak of the stock market in 2007. Some initial holdings in the banks also didn’t help, although to be fair to Mr Mott he soon changed this.
He has been wary and far from convinced we have fully recovered from the excesses of the early and mid-2000s, and preferred to invest in larger, more defensive companies which tend to be less reliant on strong economic growth for success. With hindsight it is plain to see small and medium-sized high yield companies were the best areas in which to invest.
Many investors question my continued faith in Mr Mott, but I believe PSigma’s merger with Miton Investment Managers last year will be positive for the fund; I’m not ready to write it off yet. Gervais Williams, a highly successful small and medium-sized company fund manager, will support Mr Mott on a day-to-day basis. While not directly involved with this fund, the emerging talent of George Godber also adds strength to the wider team. This new structure should bring forward better stock ideas to complement Mr Mott’s underlying, and usually correct, economic views.
The influence of Mr Williams is already being felt. He added Quindell; a consulting, software and outsourcing specialist, to the portfolio and initial results are encouraging. It is one of Mr Williams’s top stocks from his other funds and while it is currently quoted on AIM it is expected to step up to the FTSE 250 index in due course.
The fund is not going to become small and mid-cap oriented. It is expected to have 10 to 15 per cent exposure to this area. Elsewhere, Mr Mott continues to focus on the pharmaceutical and biotechnology theme, where around 20 per cent of the fund is invested. He remains convinced these sectors will “embark on a multi-year opportunity”. Key holdings are GlaxoSmithKline and AstraZeneca in the UK; and Novartis, Roche and Bristol-Myers Squibb overseas.
Overall, the team asks itself five simple questions: what are the prospects for a rise in turnover? Can corporate margins be sustained? Is the management team good enough? How much financial headroom is there in the balance sheet? Are there low expectations in the share price?
This system helps give the team an objective view on each company. Examples include SSE, which has a balance sheet that looks worse than first appears; and food retailers such as Tesco and Sainsbury’s which are losing market share. These positions have now been sold.
New additions to the fund have included Royal Mail and Stobart Group.
I think its bias to larger companies might begin to pay off over the next few years, as this area is beginning to look good value relative to smaller and medium-sized companies which have had such a good run recently.
Mark Dampier is head of research at Hargreaves Lansdown, the asset manager, financial adviser and stockbroker. For more details about the funds included in this column, visit hl.co.uk/independent
When you beloved this post along with you wish to acquire more information regarding รีวิวร้านอาหาร generously pay a visit to our own site.